Diabetes-Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes Mellitus Risk Enhancers Long duration ( 10 years for type 2 diabetes mellitusS4.3-20 or 20 years for type 1 diabetes mellitusS4.3-6 Albuminuria 30 mcg of albumin/mg creatinineS4.3-25 ABI indicates ankle-brachial index; and eGFR, estimated glomerular filtration rate. CLINICAL STATEMENTS AND GUIDELINES 5. According to a CTT analysis,S4.3-12 the higher the 10-year ASCVD risk, the greater is the ben- efit from increased LDL-C reduction. This is supported by the meta-analyses comparing high- intensity versus -low-intensity statin therapyS4.3-12 and those comparing the benefit of statins and nonstatin therapeutic agents (ie, ezetimibe, bile sequestrants, PCSK9 antagonists) that upregu- late LDL receptors.S4.3-27 Therefore, a risk discus- sion may be held on the benefits of achieving 50% LDL-C lowering in adults with diabetes mellitus who have 20% ASCVD risk. Addition of ezetimibe 10 mg/d to moderate-intensity statin therapy can achieve the same percent LDL-C low- ering as that achieved with high-intensity statin In this RCT, 27% of patients had Thus, ezetimibe added to a moderate-intensity statin can be considered if a high-intensity statin cannot be tolerated or does not lower LDL-C, as expected, by 50%. 6. Although the risk of ASCVD is high in adults >75 years of age with diabetes mellitusS4.3-5,S4.3-6,S4.3-8 who are not receiving statin therapy, particularly those with additional risk factors or risk modifi- ers, the benefit of initiating statin therapy in these individuals may be limited by their reduced life span or increased susceptibility to adverse effects of treatment. Among this group will also be indi- viduals with recent or newly diagnosed diabetes mellitus for whom the impact of diabetes mellitus on ASCVD risk is not well known. 